Published in Gastroenterology on October 05, 2007
Biology and treatment of eosinophilic esophagitis. Gastroenterology (2009) 2.18
Seasonal variation in detection of oesophageal eosinophilia and eosinophilic oesophagitis. Aliment Pharmacol Ther (2015) 1.99
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol (2012) 1.79
Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol (2008) 1.79
Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy (2009) 1.64
Outcomes of Esophageal Dilation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype. Am J Gastroenterol (2016) 1.61
Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am (2009) 1.51
MMPs-2 and -14 Are Elevated in Eosinophilic Esophagitis and Reduced Following Topical Corticosteroid Therapy. J Pediatr Gastroenterol Nutr (2015) 1.43
The expanding role(s) of eosinophils in health and disease. Blood (2012) 1.35
High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol (2013) 1.35
What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol (2010) 1.33
Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm Res (2011) 1.24
Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol (2012) 1.20
Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis. Gastroenterol Clin North Am (2014) 1.19
Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2011) 1.15
Molecular, genetic, and cellular bases for treating eosinophilic esophagitis. Gastroenterology (2015) 1.11
Eosinophilic esophagitis. World J Gastroenterol (2009) 1.09
Allergy and eosinophil-associated gastrointestinal disorders (EGID). Curr Opin Immunol (2008) 1.09
Esophageal functional impairments in experimental eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol (2012) 1.09
Eosinophilic esophagitis: the newest esophageal inflammatory disease. Nat Rev Gastroenterol Hepatol (2009) 1.09
Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol (2013) 1.08
Allergic mechanisms in eosinophilic esophagitis. Gastroenterol Clin North Am (2014) 1.08
TGF-β1-induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis. J Allergy Clin Immunol (2014) 1.01
FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis. Gut (2008) 1.01
The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis. Gastrointest Endosc (2015) 1.01
Pathogenic role of mast cells in experimental eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol (2013) 0.98
Indoor insect allergens are potent inducers of experimental eosinophilic esophagitis in mice. J Leukoc Biol (2010) 0.96
CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. Am J Pathol (2011) 0.95
Therapeutic concepts in adult and paediatric eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol (2012) 0.94
Mechanism of eosinophilic esophagitis. Immunol Allergy Clin North Am (2009) 0.93
Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One (2012) 0.92
Recent advances in the pathological understanding of eosinophilic esophagitis. Expert Rev Gastroenterol Hepatol (2015) 0.92
Roles and regulation of gastrointestinal eosinophils in immunity and disease. J Immunol (2014) 0.91
Smad3-deficient mice have reduced esophageal fibrosis and angiogenesis in a model of egg-induced eosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2014) 0.90
Targeted ablation of miR-21 decreases murine eosinophil progenitor cell growth. PLoS One (2013) 0.90
Pathogenesis of allergen-induced eosinophilic esophagitis is independent of interleukin (IL)-13. Immunol Cell Biol (2013) 0.88
Remodeling and fibrosis in chronic eosinophil inflammation. Dig Dis (2014) 0.88
Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am (2015) 0.87
TGF-β1: Mediator of a feedback loop in eosinophilic esophagitis--or should we really say mastocytic esophagitis? J Allergy Clin Immunol (2010) 0.86
Invariant natural killer T-cell neutralization is a possible novel therapy for human eosinophilic esophagitis. Clin Transl Immunology (2014) 0.85
Activated eosinophils in association with enteric nerves in inflammatory bowel disease. PLoS One (2013) 0.84
Eosinophilic gastrointestinal diseases--clinically diverse and histopathologically confounding. Semin Immunopathol (2012) 0.84
Mechanisms of Disease of Eosinophilic Esophagitis. Annu Rev Pathol (2016) 0.81
Involvement of interleukin-18 in the pathogenesis of human eosinophilic esophagitis. Clin Immunol (2015) 0.80
Misregulation of suppressors of cytokine signaling in eosinophilic esophagitis. J Gastroenterol (2012) 0.80
Allergic mechanisms of Eosinophilic oesophagitis. Best Pract Res Clin Gastroenterol (2015) 0.79
Diagnostic and therapeutic strategies for eosinophilic esophagitis. Clin Pract (Lond) (2014) 0.78
The pathogenesis of eosinophilic esophagitis: beyond the eosinophil. Dig Dis Sci (2013) 0.78
TGF-β1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis. J Allergy Clin Immunol (2016) 0.77
The pathophysiology of eosinophilic esophagitis. Front Pediatr (2014) 0.77
Food and aeroallergens in eosinophilic esophagitis: role of the allergist in patient management. Curr Opin Gastroenterol (2014) 0.77
Immunotherapeutic approaches for the treatment of eosinophilic esophagitis. Immunotherapy (2014) 0.77
The Immunologic Mechanisms of Eosinophilic Esophagitis. Curr Allergy Asthma Rep (2016) 0.77
Significance of Mouse Models in Dissecting the Mechanism of Human Eosinophilic Gastrointestinal Diseases (EGID). J Gastroenterol Hepatol Res (2015) 0.76
Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice. Curr Treat Options Gastroenterol (2015) 0.76
Elements Involved In Promoting Eosinophilic Gastrointestinal Disorders. J Genet Syndr Gene Ther (2015) 0.76
Diagnosis and treatment of eosinophilic esophagitis. F1000 Med Rep (2009) 0.75
Do We Know What Causes Eosinophilic Esophagitis? A Mechanistic Update. Curr Gastroenterol Rep (2015) 0.75
Recent discoveries and emerging therapeutics in eosinophilic esophagitis. World J Gastrointest Pharmacol Ther (2016) 0.75
Esophageal human β-defensin expression in eosinophilic esophagitis. Pediatr Res (2013) 0.75
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med (2000) 5.82
A critical role for eosinophils in allergic airways remodeling. Science (2004) 5.53
Idiopathic pulmonary fibrosis. N Engl J Med (2001) 5.49
Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology (2003) 5.36
Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med (2002) 5.07
Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol (2004) 4.69
Eosinophilia. N Engl J Med (1998) 4.14
Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med (2001) 3.59
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol (2006) 3.51
Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol (2005) 3.34
An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest (2001) 3.32
Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis (1989) 3.06
Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2007) 2.95
Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol (1997) 2.84
Dual roles of IL-4 in lung injury and fibrosis. J Immunol (2003) 2.75
Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology (2003) 2.40
IL-5 promotes eosinophil trafficking to the esophagus. J Immunol (2002) 2.06
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs (2004) 2.05
Eosinophilic esophagitis in adults: distinguishing features from gastroesophageal reflux disease: a study of 41 patients. Mod Pathol (2006) 1.89
Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol (2004) 1.87
IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol (2002) 1.81
The biology of the eosinophilic leukocyte. Annu Rev Med (1993) 1.65
Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr (2007) 1.58
A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A (2006) 1.55
Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem (2002) 1.54
A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol (1995) 1.50
Expression of growth factors and remodelling of the airway wall in bronchial asthma. Thorax (1998) 1.47
Fragility of the esophageal mucosa: a pathognomonic endoscopic sign of primary eosinophilic esophagitis? Gastrointest Endosc (2003) 1.46
Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol (2002) 1.45
Eosinophil trafficking to sites of allergic inflammation. Immunol Rev (2001) 1.22
Eosinophils in allergy: role in disease, degranulation, and cytokines. Int Arch Allergy Immunol (1996) 1.14
Activated eosinophils in esophagitis in children: a transmission electron microscopic study. J Pediatr Gastroenterol Nutr (1997) 1.14
Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Hum Pathol (2006) 1.08
Reflux esophagitis: sequelae and differential diagnosis in infants and children including eosinophilic esophagitis. Pediatr Dev Pathol (2004) 1.05
Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. J Biol Chem (2001) 1.01
Eosinophils in the esophagus: acid is not the only cause. J Pediatr Gastroenterol Nutr (1998) 1.00
Airway inflammation and remodeling in asthma. Lessons from interleukin 11 and interleukin 13 transgenic mice. Am J Respir Crit Care Med (2001) 0.98
Mucin biosynthesis: epidermal growth factor downregulates core 2 enzymes in a human airway adenocarcinoma cell line. Am J Respir Cell Mol Biol (2003) 0.83
[Eosinophilic esophagitis: a novel entity?]. Praxis (Bern 1994) (2006) 0.80
Reduced airway inflammation and remodeling in parallel with mucin 5AC protein expression decreased by s-carboxymethylcysteine, a mucoregulant, in the airways of rats exposed to sulfur dioxide. Int Arch Allergy Immunol (2004) 0.78
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest (2006) 5.48
Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature (2008) 4.85
Eosinophilic esophagitis. N Engl J Med (2004) 4.43
Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest (2003) 4.08
Eosinophils: biological properties and role in health and disease. Clin Exp Allergy (2008) 3.92
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology (2006) 3.68
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol (2006) 3.51
Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2012) 3.45
IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol (2007) 3.24
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol (2006) 3.04
MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol (2009) 2.89
Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 2.74
Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet (2010) 2.47
Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology (2003) 2.40
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
Foxa2 regulates alveolarization and goblet cell hyperplasia. Development (2004) 2.35
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol (2003) 2.31
IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med (2008) 2.19
Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol (2007) 2.18
Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest (2003) 2.17
Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol (2008) 2.12
IL-5 promotes eosinophil trafficking to the esophagus. J Immunol (2002) 2.06
Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol (2003) 2.06
Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med (2002) 2.04
Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol (2008) 2.04
Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol (2010) 2.00
MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol (2011) 2.00
Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med (2009) 1.97
Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol (2010) 1.92
Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol (2004) 1.87
Importance of cytokines in murine allergic airway disease and human asthma. J Immunol (2010) 1.86
Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2003) 1.86
Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol (2010) 1.85
Resistin-like molecule-beta is an allergen-induced cytokine with inflammatory and remodeling activity in the murine lung. Am J Physiol Lung Cell Mol Physiol (2007) 1.85
Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol (2006) 1.84
A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol (2011) 1.82
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol (2011) 1.82
Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol (2005) 1.80
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol (2012) 1.79
Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol (2006) 1.79
Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology (2005) 1.78
Prevalence and outcome of allergic colitis in healthy infants with rectal bleeding: a prospective cohort study. J Pediatr Gastroenterol Nutr (2005) 1.78
Biology of the eosinophil. Adv Immunol (2009) 1.74
Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol (2010) 1.74